Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 344.31 is 180% above its 3-year average of 122.85, near the high end of its 3-year range (9.63–344.31).
As of the fiscal period ended Wednesday, December 31, 2025. 51.27% above its 12-month average of 227.61.
Reported quarterly quick ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 344.31.
QUICK RATIO (ACID-TEST)
344.31
QUICK RATIO (ACID-TEST) AVG TTM
227.61
QUICK RATIO (ACID-TEST) AVG 3Y
122.85
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+51.27%
CURRENT VS 3Y AVG
+180.28%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+10177.93%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$210.68M
Quick Ratio (Acid-Test)
344.31
TTM Avg
227.61
3Y Avg
122.85
5Y Avg
N/A
Market Cap
$214.89M
Quick Ratio (Acid-Test)
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$213.84M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$213.86M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$211.80M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$210.80M
Quick Ratio (Acid-Test)
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
Market Cap
$208.20M
Quick Ratio (Acid-Test)
2.45
TTM Avg
2.08
3Y Avg
1.84
5Y Avg
1.77
Market Cap
$208.98M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$222.26M
Quick Ratio (Acid-Test)
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $210.68M | 344.31 | 227.61 | 122.85 | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.89M | 4.07 | 3.65 | 6.88 | 10.38 |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 5.13 | 3.45 | 2.59 | 2.27 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.86M | 5.36 | 6.17 | 11.50 | 11.99 |
| Compugen Ltd. (CGEN)vs › | $211.80M | 5.72 | 5.91 | 5.85 | 7.15 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.80M | 10.89 | 11.84 | 8.89 | 15.32 |
| Pro-Dex, Inc. (PDEX)vs › | $208.20M | 2.45 | 2.08 | 1.84 | 1.77 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.98M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $222.26M | 21.96 | 18.45 | 17.11 | 21.15 |
| Profound Medical Corp. (PROF)vs › | $222.74M | 5.31 | 10.41 | 9.80 | 12.54 |
Quick Ratio
344.31
Excludes inventory
Current Ratio
344.31
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 344.31 |
| 2025-09-30 | 344.31 |
| 2025-06-30 | 211.10 |
| 2024-12-31 | 10.71 |
| 2024-06-30 | 35.56 |
| 2023-12-31 | 15.86 |
| 2023-06-30 | 11.29 |
| 2022-12-31 | 9.63 |
